中老年维持性血液透析患者死亡事件的原因分析

目的分析2005年1月～2011年12月在北京医院维持性血液透析死亡患者的病例特点和死亡原因。方法回顾性的检出维持血液透析大于3个月的死亡患者共83例,计算本中心从2005年起每年维持透析患者的死亡人数和死亡率;将死亡患者根据年龄分为3组,60岁以下中年组,60～79岁老年组和80岁以上高龄组,分析3组的人口学资料、有无糖尿病、透析龄和死亡原因等。结果从2005年起,北京医院每年维持透析患者的死亡率依次为11.00%,10.90%,8.30%。8.10%,10.10%,8.70%和6.34%;83例死亡患者中,男性49例,女性34例,平均年龄71.812.0岁(42岁～94)岁,中年组(小于60岁)14例,老年组(60～79)岁46例,高龄组(大于80)岁23例;3组患者在性别上无统计学差异。透析龄在中年组最长,平均77.2±73.0月,高龄组为44.0±35.5月,老年组透析龄最短,平均为33.2±28.1月;3组之间的差异有统计学意义。老年组患者糖尿病肾病居多;死亡原因在各组有明显的差别,中年组50%死于脑血管疾病,脑出血居多;高龄组56.50%死于感染中毒性休克。老年组死亡原因较复杂,死亡率超过10%的依次为感染中毒性休克、心肌梗死或心力衰竭、肿瘤、营养不良-炎症-动脉粥样硬化综合征(Malnutrition-inflammation-atherosclerosissyndrome,MIAsyndrome)和猝死。结论北京医院单中心血液透析死亡患者绝大多数为老年患者。年龄不是决定透析预后不良的主要危险因素,糖尿病是影响预后的重要因素,不同年龄组患者死亡原因不同,中年患者脑血管疾病多见,高龄患者感染中毒性休克常见,老年患者的死亡原因多样化,包括心脑血管疾病、感染、肿瘤和MIA综合征。±     

溴莫尼定对视网膜缺血性损伤神经保护作用的实验研究

目的：探讨溴莫尼定(brimonidine)对视网膜缺血性损伤神经的保护作用。方法：新西兰大耳白兔32只，随机分为正常对照组、生理盐水治疗组、噻吗心安(timolol)治疗组、brimonidine治疗组，每组8只。后3组为损伤治疗组，通过生理盐水前房高压灌注的方法，制成视网膜缺血动物模型，在视网膜缺血前lh其结膜囊内分剐给予生理盐水、0．5％timolol眼液或0．2％brimonidine眼液局部治疗。在灌注后7d，观察图形视网膜电图(P-ERG)b波振幅变化，并进行组织形态学观察和视网膜神经节细胞(RGC)计数分析。结果：灌注后7d，3个损伤治疗组相对b波振幅恢复率为：7％、11％和64％，RGC标准丢失率为：43％、38％和12％，brimori-die治疗组视网膜组织形态结构接近正常对照组，而生理盐水治疗组和timolol治疗组视网膜内层组织结构损伤明显。结论：Brimonidine局部治疗对缺血诱导的视网膜结构和功能的损害有明显的神经保护作用。     

灯盏花素对豚鼠单一心室肌细胞ICa的抑制作用

目的：观察灯盏花素对豚鼠单一心室肌细胞钙离子电流（ＩＣａ）的影响。方法：应用全细胞膜片钳制技术。结果：灯盏花素能明显抑制心室肌细胞的Ｃａ＾２＋通道,使ＩＣａ减小。此作用有明显的电压依赖性。在峰电流电压下作用最明显,而对其反转电位无明显影响。在指令电位０ｍＶ时,０．５ｍｇ％灯盏花素使ＩＣａ减小５．４％,１ｍｇ％灯盏花素使ＩＣａ减小２２．９％（Ｐ〈０．０１）,２ｍｇ％灯盏花素使ＩＣａ减小４５．０％（Ｐ     

抗病毒药物2，5，6-三取代－4（3H）嘧啶酮衍生物的合成及诱导干扰素活性

抗病毒药物２，５，６-三取代－４（３Ｈ）嘧啶酮衍生物的合成及诱导干扰素活性刘新泳，徐丽君（山东医科大学药学系济南２５００１２）取代嘧啶酮类化合物是一类小分干扰素诱导剂，有抗病毒、抗肿瘤、杀菌抑霉、诱导干扰素和白介素、免疫调节等多种生物活性（１）。目前?..     

Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is associated with reduced intensive care unit mortality: a prospective analysis

IntroductionAcute respiratory distress syndrome (ARDS) is a common clinical syndrome with high mortality and long-term morbidity. To date there is no effective pharmacological therapy. Aspirin therapy has recently been shown to reduce the risk of developing ARDS, but the effect of aspirin on established ARDS is unknown.MethodsIn a single large regional medical and surgical ICU between December 2010 and July 2012, all patients with ARDS were prospectively identified and demographic, clinical, and laboratory variables were recorded retrospectively. Aspirin usage, both pre-hospital and during intensive care unit (ICU) stay, was included. The primary outcome was ICU mortality. We used univariate and multivariate logistic regression analyses to assess the impact of these variables on ICU mortality.ResultsIn total, 202 patients with ARDS were included; 56 (28%) of these received aspirin either pre-hospital, in the ICU, or both. Using multivariate logistic regression analysis, aspirin therapy, given either before or during hospital stay, was associated with a reduction in ICU mortality (odds ratio (OR) 0.38 (0.15 to 0.96) P = 0.04). Additional factors that predicted ICU mortality for patients with ARDS were vasopressor use (OR 2.09 (1.05 to 4.18) P = 0.04) and APACHE II score (OR 1.07 (1.02 to 1.13) P = 0.01). There was no effect upon ICU length of stay or hospital mortality.ConclusionAspirin therapy was associated with a reduced risk of ICU mortality. These data are the first to demonstrate a potential protective role for aspirin in patients with ARDS. Clinical trials to evaluate the role of aspirin as a pharmacological intervention for ARDS are needed.     

Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest

In this report, we extend our previous findings that IgG or F(ab')2 fragments of HD37 anti-CD19 antibody (Ab) in combination with the immunotoxin (IT), RFB4-anti-CD22-deglycosylated ricin A chain (dgA) (but neither reagent alone), prolonged the survival of SCID mice with disseminated human Daudi lymphoma (SCID/Daudi mice) to 1 year at which time they still remained tumor-free. We explored the mechanisms by which the HD37 Ab exerts antitumor activity in vivo by studying its activity in vitro. We found that it has antiproliferative activity (IC50 = 5.2 - 9.8 x 10(-7) mol/L) on three CD19+ Burkitt's lymphoma cell lines (Daudi, Raji, and Namalwa) but not on a weakly CD19-positive (CD19lo) pre-B cell tumor (Nalm-6). The inhibitory effect was manifested by cell cycle arrest, but not apoptosis. Results using three additional anti-CD19 Abs, suggest that the affinity of the antibody and possibly the epitope which it recognizes may effect its capacity to transmit a signal that induces cell cycle arrest. Hence, therapeutically useful Abs may exert anti-tumor activity by a variety of mechanisms, each of which should be evaluated before undertaking clinical trials in humans.     

Studies of circulating hemopoietic progenitor cells in human fetal blood

High levels of committed erythroid and granulocytic/monocytic progenitor cells have been demonstrated in fresh blood obtained at fetoscopy. The fetal progenitor cells were more sensitive to appropriate stimuli (erythropoietin and colony-stimulating factor) than adult progenitor cells grown under the same conditions, and this was shown to be due to intrinsic differences in the progenitor cells at the different developmental stages.